Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: PillCam Colon Clearance; CGM For Pediatrics; SGR Reform Bill

This article was originally published in The Gray Sheet

Executive Summary

Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.

You may also be interested in...



Market Intel: Robotic Pills And The Future Of Painless Drug Delivery

Robotic pill technology, which is already being used for diagnostic purposes, will likely be embraced for the oral delivery of biologic drugs as well. Biologic therapies currently require injections in most cases, but some are exploring specialized robotic pills as a pain-free approach that could increase convenience and compliance, and thus efficacy, of medicines. Several established companies and research centers are working on both diagnostic and biologic therapeutic applications of pill-based technologies.

Transparency Advocates Work To Release Health Care Pricing Data

Policymakers and transparency advocates at U.S. Chamber of Commerce forum March 24 pushed legislation, strategies to give patients the tools for comparison shopping different procedures.

DexCom Hit With FDA Warning Letter For Adverse Event Deficiencies

The firm says an FDA warning letter it received cites violations based on “recent updates” to FDA’s Medical Device Reporting program made in a draft guidance last year. But FDA emphasizes that it does not take enforcement actions based on how a company implements a guidance document, draft or final.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT033604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel